Pacific Biosciences of California, Inc. Operating Lease, Payments
Pacific Biosciences of California, Inc. (PACB) reported Operating Lease, Payments of $8.76 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2024-02-28
- Pacific Biosciences of California, Inc. operating lease, payments for the quarter ending 2022-12-31 was $1.82M, a 3.41% increase year-over-year.
- Pacific Biosciences of California, Inc. operating lease, payments for the quarter ending 2022-09-30 was $2.07M, a 90.62% increase year-over-year.
- Pacific Biosciences of California, Inc. operating lease, payments for the quarter ending 2022-06-30 was $1.95M, a 80.80% increase year-over-year.
- Pacific Biosciences of California, Inc. operating lease, payments for the quarter ending 2022-03-31 was $1.88M, a 76.74% increase year-over-year.
- Pacific Biosciences of California, Inc. operating lease, payments for fiscal 2023 was $8.76M, a 13.40% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. operating lease, payments for fiscal 2022 was $7.72M, a 54.79% increase from fiscal 2021.
- Pacific Biosciences of California, Inc. operating lease, payments for fiscal 2021 was $4.99M, a 31.25% increase from fiscal 2020.
- Pacific Biosciences of California, Inc. operating lease, payments for fiscal 2020 was $3.80M, a 10.91% increase from fiscal 2019.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $8.76M 10-K · filed 2024-02-28 | ||||
| 2022-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.89M derived: sum of 2 quarters · filed 2024-02-28 | $5.84M derived: sum of 3 quarters · filed 2024-02-28 | $7.72M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.02M derived: sum of 2 quarters · filed 2022-11-08 | $5.91M 10-Q · filed 2022-11-08 | $7.66M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.83M 10-Q · filed 2022-08-08 | $5.59M derived: sum of 3 quarters · filed 2024-02-28 | $6.68M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $1.88M 10-Q · filed 2022-05-06 | $3.64M derived: sum of 2 quarters · filed 2024-02-28 | $4.73M derived: sum of 3 quarters · filed 2024-02-28 | $5.81M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.85M derived: sum of 2 quarters · filed 2024-02-28 | $3.92M derived: sum of 3 quarters · filed 2024-02-28 | $4.99M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.17M derived: sum of 2 quarters · filed 2022-11-08 | $3.23M 10-Q · filed 2022-11-08 | $4.24M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.14M 10-Q · filed 2022-08-08 | $3.15M derived: sum of 3 quarters · filed 2023-02-28 | $4.11M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $1.07M 10-Q · filed 2022-05-06 | $2.08M derived: sum of 2 quarters · filed 2023-02-28 | $3.03M derived: sum of 3 quarters · filed 2023-02-28 | $3.94M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.97M derived: sum of 2 quarters · filed 2023-02-28 | $2.87M derived: sum of 3 quarters · filed 2023-02-28 | $3.80M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $956.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $1.86M derived: sum of 2 quarters · filed 2021-11-05 | $2.79M 10-Q · filed 2021-11-05 | $3.68M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $904.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $1.83M 10-Q · filed 2021-08-06 | $2.73M derived: sum of 3 quarters · filed 2022-02-28 | $3.59M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $931.00K 10-Q · filed 2021-05-06 | $1.82M derived: sum of 2 quarters · filed 2022-02-28 | $2.68M derived: sum of 3 quarters · filed 2022-02-28 | $2.56M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $891.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.75M derived: sum of 2 quarters · filed 2022-02-28 | $1.63M derived: sum of 3 quarters · filed 2022-02-28 | $3.43M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $860.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $737.00K derived: sum of 2 quarters · filed 2020-11-03 | $2.54M 10-Q · filed 2020-11-03 | ||
| 2019-06-30 | -$123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.68M 10-Q · filed 2020-08-06 | $3.50M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $1.80M 10-Q · filed 2019-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |